摘要:
This invention is a novel treatment for sexual dysfunctions by administering to a subject exhibiting a sexual dysfunction compounds that upmodulate the AMPA receptor. Methods and compositions for treating sexual dysfunction are provided. Kits containing the compositions in appropriate form for administration are also provided.
摘要:
The invention provides an indene compound represented by the following general formula (I): wherein R 1 means a lower alkyl group, R 2 and R 3 denote a lower alkyl group individually or an alkylenedioxy group in combination, and R 4 and R 5 mean individually a substituted or unsubstituted lower alkyl or aryl group or in combination a substituted or unsubstituted piperidino, piperazinyl or homopiperazinyl group together with the adjacent nitrogen atom, with a proviso that not both R 4 and R 5 are a methyl group at the same time.
représente une liaison simple ou une liaison double, n représente un entier compris entre 1 et 6 inclus, R 1 , R 2 représentent un groupement choisi parmi atome d'hydrogène, groupement alkyle (C 1 -C 6 ) linéaire ou ramifié, aryle, arylalkyle, cycloalkyle, cycloalkylalkyle, alkényle, alkynyle, hétérocycloalkyle, hétérocycloalkylalkyle, hétéroaryle, et hétéroarylalkyle, X représente un groupement choisi parmi -CH=CH-, atome d'oxygène, groupement S(O) m dans lequel m est un entier compris entre 0 et 2 inclus, et NR 3 dans lequel R 3 représente un groupement tel que défini dans la description, Y représente un groupement CH ou CH 2 selon que -------- représente une liaison simple ou une liaison double, ou peut prendre la définition supplémentaire atome d'oxygène quand X représente un atome d'oxygène, T représente un groupement cycloalkyle (C 3 -C 10 ) monocyclique ou polycyclique contenant éventuellement au sein du système cyclique un atome d'oxygène, un atome de sélénium, un groupement de formule S(O) p , NR 3 , ou SiR 4 R 5 dans lesquels p, R 3 , R 4 et R 5 sont tels que définis dans la description, leurs isomères ainsi que leurs sels d'addition à un acide ou à une base pharmaceutiquement acceptable. Médicaments.
摘要翻译:杂环烷基和杂芳基苯并环丁烷衍生物(I)是新的。 杂环烷基和杂芳基苯并环丁烷衍生物(Ⅰ)及其异构体和盐,酸和碱是新的。 虚线=单键或双键; N = 1-6; R1,R2 = H,1-6C烷基,芳基,芳基烷基,环烷基,环烷基烷基,2-6C烯基或炔基,杂环烷基,杂环烷基烷基,杂芳基,或杂芳烷基; X = -CH = CH-,-O - , - S(O)m-或-N(R 3) - ; N = 0-2; R3 = H,1-6C烷基,芳基,芳基烷基,环烷基,环烷基烷基,或2-6C烯基或炔基; Y = CH或CH 2取决于它是由单键或双键相连,或者它可以是O当X是O; T = 3-12C单环或多环环烷基,其中的C原子中的一个可以被O,硒,SOP,R3或SiR4R5取代; P = 0-2; R4,R5 = 1-6C烷基。 卤素,1-6C-烷基或:内(I)的定义中,芳基可以是苯基,联苯基,萘基,二氢萘基,四氢萘基,茚满基,茚基,苯并环丁基或,其中的每一个可以由一个或多个以下的被substituiertem 烷氧基,OH,NO 2,CN,三卤代1-6C,NH 2,或单 - 或二 - 烷基氨基,杂芳基在芳基包括上文中所述循环系统含有1-3个杂原子(O,N,S)所定义和 如之前OPTIONALLY substituiertem,环烷基可以是单环或多环的3-12成员,任选地含有不饱和度并如前OPTIONALLY substituiertem,和杂环基团包含环烷基基团所定义并可以具有一个或多个不饱和度和含有1-3个杂原子 (O,N,S)的环。 因此独立claimsoft被包括为(I)的制剂。
摘要:
This invention is directed to halodihydrodioxins, their preparation and their polymers, which provide amorphous homopolymers that are resistant to ring opening side reactions. The resulting polymers can be used for films and thermally stable molded objects, coatings for substrates such as wood, glass, paper and metal and for protective packaging. This invention also concerns the preparation of polyhalogenated dioxoles.
摘要:
A novel fluorene characterized by having a fluorene skeleton to which a functional group such as a guanidino group is attached via a carbonyl group, or its salt. This compound has such an advantage as showing a high affinity particularly for 5-HT2B receptor and 5-HT7 receptor, among serotonin receptor subtypes, and exhibiting an excellent pharmacological effect compared with a conventional compound having an antagonistic activity to only one of the 5-HT2B receptor and 5-HT7 receptor. Thus, it is useful as a highly efficacious and safe preventive for migraine.
摘要:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.